Medication info
Pregabalin Oral Disintegrating Tablets 50 mg (Pregabalin)

Pregabalin Oral Disintegrating Tablets 50 mg (Pregabalin)

Prescription medicationOrally disintegrating Tablet
Ingredient · strength
Pregabalin›50mg / 1 tablet
Manufacturer / importer
Hanol Bio Pharma Co., Ltd.
Appearance
Yellow round oral disintegrating tablet
Packaging
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Approval status
Active

MFDS item code 202600532 · Approved 2026.02.24

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Place it on the tongue and, once it has disintegrated, swallow it without water. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12-17 years: Administration is not recommended.

Ingredients

Manufacturer
Hanol Bio Pharma Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy and is effective whether or not there are secondary general symptoms. Additionally, it helps in the treatment of fibromyalgia. In summary, it is used to improve symptoms of neuropathic pain, partial seizures in epilepsy, and fibromyalgia.

Dosage and Administration

Adult dosage

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Place it on the tongue and, once it has disintegrated, swallow it without water. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with hepatic impairment Dose adjustment is not required in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended. Adolescent patients aged 12-17 years: Administration is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so if symptoms of depression or mood changes occur during treatment, it must be reported to a healthcare professional immediately. It should not be used if there is an allergy to this medication's components. Diabetic patients may need to adjust their blood sugar control medications due to weight gain after taking this medication. If allergic reactions such as angioedema occur, discontinue use immediately and consult a healthcare professional. Elderly patients need to be cautious of falls or injuries due to dizziness or drowsiness and should refrain from activities if these symptoms occur. This medication may cause blurred vision, so any changes in vision should be reported to a healthcare professional. Halting this medication suddenly can cause withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually reduced after consulting a healthcare professional. Patients with a history of drug abuse should be especially cautious of misuse or dependence on this medication. Patients with decreased kidney function may require dose adjustments of this medication. Patients with severe heart disease should use this medication cautiously and consult a healthcare professional immediately if symptoms of heart failure occur. Taking this medication with other central nervous system depressants or opioid analgesics can increase the risk of respiratory depression, so caution is needed. During early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant should consult a healthcare professional before taking this medication and use effective contraception. Breastfeeding women should discuss with a healthcare professional regarding the potential transfer of this medication into breast milk and its effects on the infant. It is advisable to avoid dangerous activities such as driving or operating machinery until dizziness or drowsiness symptoms subside. Severe skin reactions may occur, so if symptoms such as rash, redness, or blisters arise, discontinue use immediately and inform a healthcare professional. In cases of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, so immediate medical attention should be sought for appropriate treatment. This medication must be stored out of reach of children and should not be transferred to other containers for safety.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 186 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • visual changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • gloom
  • thoughts of suicide
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • sense of well-being
  • decreased libido
  • depersonalization
  • sexual dysfunction
  • anxiety
  • mood swings
  • lowered emotions
  • elevated emotions
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • disinhibition
  • apathy
  • ataxia
  • dyscoordination
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • reduced mobility
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • diplopia
  • dry eyes
  • eyelid swelling
  • vision reduction
  • eye pain
  • eye fatigue
  • increased tear secretion
  • ocular irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • bradycardia
  • arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distention
  • constipation
  • dry mouth
  • flatulence
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle twitching
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • swelling
  • gait abnormalities
  • falls
  • intoxicated feeling
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • headache
  • loss of consciousness
  • mental disorder
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • mood disorders
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow round oral disintegrating tablet

Package unit

30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.